Safety profile and clinical recommendations for the use of lapatinib

Breast Care

Volumn 5, Issue SUPPL. 1, 2010, Pages 16-21

  Chatsiproios, Dimitrios ^a  

^a Gynäkologisch onkologische Praxis Kreuzlingen ^*  (Switzerland)

Author keywords

Clinical management; Diarrhea; Lapatinib; Rash; Tolerability

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GASTROINTESTINAL AGENT; HERBACEOUS AGENT; LAPATINIB; OCTREOTIDE; PACLITAXEL; PROTEINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CARDIAC GATED IMAGING; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ECHOCARDIOGRAPHY; EDEMA; ERYTHEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HAIR DISEASE; HAND FOOT SYNDROME; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERKERATOSIS; MONOTHERAPY; NAIL DISEASE; NAUSEA; PATIENT EDUCATION; PRIORITY JOURNAL; PRURITUS; PUSTULE; RASH; REVIEW; SENSORY DYSFUNCTION; SEPSIS; SIDE EFFECT; SKIN DISEASE; SKIN FISSURE; SKIN INFECTION; URTICARIA; VOMITING;

EID: 77952849788     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000285776     Document Type: Review

References (23)

1. O'Keefe E, Battin T, Payne T Jr: Epidermal growth factor receptor in human epidermal cells: direct demonstration in cultured cells. J Invest Dermatol 1982;78:482-487.
2. Harandi A, Zaida A, Stocker AM, Laber D: Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009; Epub ahead of print.
3. Moy B, Goss PE: Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007;12:756-765.
4. Geyer CE, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER-2-positive advanced breast Cancer. N Engl J Med 2006;355:2733-2743.
5. Di Leo A, Gomez HL, Aziz Z, et al.: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-5552.
6. Crown JP, Burris HA, Jones S, et al.: Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC). J Clin Oncol 2007;25(suppl):38s, abstr 1027.
7. Jones SF, Burris HA 3rd, Yardley DA, et al.: Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel. 27th Annual San Antonio Breast Cancer Symposium 2004;abstr 1069.
8. Crown JP, Burris HA 3rd, Boyle F, et al.: Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008;112:317-325.
9. Arbuckle RB, Huber SL, Zacker C: The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 2000;5:250-259.
10. Benson AB, Ajani JA, Catalano RB: Recommended guidelines for treatment of cancer treatment- induced diarrhea. J Clin Oncol 2004;22:2918-2926
11. Cascinu S, Barni S, Labianca R: Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer study. Support Care Cancer 1997;5:314-317.
12. Rothenberg ML, Meropol NJ, Poplin EA: Mortality associated with irinotecan plus bolus fluorouracil/ leucovorin: summary findings of an independent panel. J Clin Oncol 2110;19:3801-3807.
13. Rosenoff S: Octreotide LAR resolves severe chemotherapy-induced diarrhea and allows continuation of full-dose therapy. Proc Am Soc Oncol 2003;22:778(abstr 3126).
14. Wadler S, Benson AB, Engelking C: Recommended guidelines for the treatment of cheomtherapyinduced diarrhea. J Clin Oncol 1998;16:3169-3178.
15. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433.
16. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M: Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009;16:16-26.
17. Lacouture ME, Laabs SM, Koehler M, et al.: Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2009;114:485-493.
18. Moy B and Goss PE: Lapatinib associated toxicity and practical management recommendations. Oncologist 2007;12:756-765.
19. Perez EA: Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer 2008;8(suppl 3):S114.
20. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
21. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS: Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008;83:679-686.
22. Ewer MS, Perez EA, Baselga J, et al.: Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin) in HER2-positive early breast cancer. Breast 2007;16(suppl 1):S63.
23. Tyverb® full prescribing information, August 2009; us.gsk.com/products/assets/us-tykerb.pdf.